Should baseline/routine ECG monitoring be performed for patients on buprenorphine-containing medications? [0.03%]
布鼻芬相关药物治疗患者的常规心电图监测必要性探讨
Kayla Boedeker,Megan Fraley,Sarah Toppins et al.
Kayla Boedeker et al.
Buprenorphine: Opioid Agonist-Antagonist for Refractory Pain of Sickle Cell Disease Patients During Hematopoietic Stem Cell Transplant, Uncontrolled By Full-Agonist Opioids [0.03%]
对造血干细胞移植期间完全激动剂类阿片类药物无法控制的镰状细胞病患者的难治性疼痛具有拮抗作用的白细胞介素-18激动剂布洛芬治疗
Mayuko Sakae
Mayuko Sakae
Background: Bone marrow transplant (BMT) offers potential cure for cancer and a spectrum of otherwise incur- able diseases. The BMT process can cause multi-systemic pain in patients with sickle cell disease (SCD) refracto...
Impact of an Education Module on the Knowledge and Attitudes of EM Physicians Towards Prescribing Buprenorphine/Naloxone for Opioid Use Disorder [0.03%]
教育模块对急诊医师对阿片类药物使用障碍的布宁膦酸盐/纳洛酮处方知识和态度的影响
Amy Zosel,Jennifer Hernandez-Meier,Julie Owen
Amy Zosel
Background: Opioid overdose continues to be a major cause of morbidity and mortality. Buprenorphine is an important treatment for patients with opioid-use disorder (OUD) and initiation in the emergency department (ED) has...
Maria Silveira,Victoria Powell
Maria Silveira
Background: Buprenorphine may be safer and better-tolerated than full mu opioid receptor (MOR) agonists. Whether it effectively controls cancer-related pain is unclear. A prior review (Cochrane 2015) did not support prior...
Conversion of CII Opioid Medications to Buprenorphine in the Chronic Pain Population - Insights and Clinical Pearls [0.03%]
慢性疼痛人群中的CII级阿片类药物转换为丁丙诺啡的启示及临床经验
Amanda Zimmerman
Amanda Zimmerman
Background: There is a great deal of confusion associated with conversion from CII opioid to buprenorphine products. The data presented supports that patients can be converted from high dose opioid medication to buprenorp...
"My addiction doesn't define me": Healing from the stigma of addiction for mothers with opioid use disorder [0.03%]
“我的瘾君子身份并不能定义我”——海洛因成瘾妈妈的康复与污名化问题
Christine Bakos-Block,Francine Vega,A Sarah Cohen et al.
Christine Bakos-Block et al.
Background: About 1 in 8 children under age 17 live with a parent who has a substance use disorder. Research on treatment access identifies stigma as a significant barrier to treatment, particularly among mothers with you...
Jeffrey J Bettinger,Jacqueline Cleary
Jeffrey J Bettinger
Although buprenorphine use has increased dramatically over the past decade, its unique pharmacologic and pharmacokinetic profile often leads to misconceptions about its overall utility and has created a drastic underrepresentation in patien...
The "Micro"cosm: Magnifying the Nuance of Low Dose Buprenorphine Inductions [0.03%]
微调：低剂量丁丙诺啡诱导的细微差别分析
Tanya Uritsky,Emily Casey
Tanya Uritsky
Background: Now that the X-wavier is a thing of the past, patients with Opioid Use Disorder (OUD) who previously lacked access to buprenorphine may have access to lower barrier care and may be looking to make the transiti...
Marcin Chwistek,Dylan Sherry,Leigh Kinczewski
Marcin Chwistek
Background: Opioids remain the cornerstone for the treatment of moderate to severe cancer pain. Due to benefits over full agonist opioids (FAO), buprenorphine has emerged as an alternative treatment. ...
Nicole Cornish
Nicole Cornish
Background: The CPG's updated recommendation is supported by buprenorphine's lower risk of overdose and misuse.(1) In comparison to full mu-opioid agonists, buprenorphine possesses a superior safety profile with respect t...